Pharmacokinetics, Tissue Distribution, and Excretion Study of Cajanonic Acid A in Rats by UPLC-MS/MS

Abstract

Cajanonic acid A (CAA), a prenylated stilbene derivative extracted from the leaves of pigeon pea (Cajanus cajan), has been reported to possess inhibitory activity on the peroxisome proliferator-activated receptor gamma (PPARγ) and protein tyrosine phosphatase 1B (PTP1B). Its hypoglycemic activity in rats is comparable to that of the approved antidiabetic agent rosiglitazone. Therefore, CAA is a potential candidate for the treatment of type 2 diabetes and a lead compound for the discovery of novel hypoglycemic drugs. To achieve a thorough understanding of the biological behavior of CAA in vivo, our current study was designed to investigate the pharmacokinetics, bioavailability, distribution, and excretion of CAA in rats by UPLC-MS/MS. Chromatographic separation was performed on BEHC18 column (2.1 mm × 50 mm, 1.7 µm). Quantification was performed under the negative ion mode by using single reaction monitoring (SRM) of the transitions of m/z 353.14 → 309.11 for CAA and m/z 269.86 → 224.11 for genistein, respectively. Standard calibration curve showed excellent linearity (r² > 0.99) within the range of 2 – 800 ng/mL. The accuracies and precisions were within the acceptance limits (all < 20%). CAA was quickly absorbed into bloodstream and distributed rapidly and widely to various tissues. The excretion ratio of CAA in the 3 main pathways via bile, feces, and urine was only 5.17%. These results indicate that CAA was quickly and thoroughly metabolized in vivo and excreted mainly as metabolites.

Key words

Pigeon pea - Cajanus cajan - Leguminosae - cajanonic acid A - pharmacokinetics - distribution - excretion - UPLC-MS/MS

• References

• 1 Association AD. 10. Microvascular complications and foot care: standards of medical care in diabetes-2018. Diabetes Care 2018; 41 (Suppl. 01) S105
• 2 Kahn BB. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell 1998; 92: 593-596
• 3 Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846
• 4 Mayerdavis EJ. Intensity and amount of physical activity in relation to insulin sensitivity: the insulin resistance atherosclerosis study. Jama J Am Med Assoc 1998; 279: 669-674
• 5 Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014; 2014: 943162
• 6 Gan SC, Barr J, Arieff AI, Pearl AG. Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med 1992; 152: 2333-2336
• 7 Rosen CJ. Revisiting the rosiglitazone story–lessons learned. N Engl J Med 2010; 363: 803-806
• 8 Edwards CMB. International textbook of diabetes mellitus. J R Soc Med 2004; 97: 554
• 9 Chen WZ, Fan LL, Xiao HT, Zhou Y, Xiao W, Wang JT, Tang L. First total synthesis of natural products of cajanolactone A and cajanonic acid A. Chin Chem Lett 2014; 25: 749-751
• 10 Qiu SX, Shen XL. Cajanus cajan L. natural medicine with blood sugar reduction and weight reduction function. Patent CN 101422450A, 2008
• 11 Shen XL, Hu YJ, Qiu SX, Wang L, Fu LC, Mai Z. Medicament useful for reducing blood sugar and body weigh having the structure of stilbene compounds. Patent WO201301347A1, 2013
• 12 Wang L. Effect and mechanism of cajanonic acid A on regulating blood glucose and serum lipid. Guangzhou: University of Chinese Medicine; 2012
• 13 Yang RY, Wang L, Xie J, Li X, Liu S, Qiu S, Shen X. Treatment of type 2 diabetes mellitus via reversing insulin resistance and regulating lipid homeostasis in vitro and in vivo using cajanonic acid A. Int J Mol Med 2018; 42: 2329-2342
• 14 Xie J. To Explore the Effect of Cajanonic Acid A on Insulin Resistance. Guangzhou: University of Chinese Medicine; 2014
• 15 Li X. To Explore the Effect of Cajanonic Acid A on the Insulin Signaling Pathway in HepG2 Cells with PTP1B Overexpression. Guangzhou: University of Chinese Medicine; 2015
• 16 Smith DA, Allerton C, Kalgutkar AS, van de Waterbeemd H, Walker DK. Pharmacokinetics and Metabolism in Drug Design. 3rd ed.. ed. Weinheim: Wiley-VCH; 2012
• 17 Di L, Kerns EH. Drug-Like Properties: Concepts, Structure Design, and Methods. Elevier: London; 2016
• 18 Cossette C, Chourey S, Ye Q, Nagendra Reddy C, Gore V, Gravel S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS. Pharmacokinetics and metabolism of selective oxoeicosanoid (OXE) receptor antagonists and their effects on 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE)-induced granulocyte activation in monkeys. J Med Chem 2016; 59: 10127-10146
• 19 Lombardo F, Desai PV, Arimoto R, Desino KE, Fischer H, Keefer CE, Petersson C, Winiwarter S, Broccatelli F. In silico absorption, distribution, metabolism, excretion and pharmacokinetics (ADME-PK): utility and best practices–an industry perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development. J Med Chem 2017; acs.jmedchem.7b00487.
• 20 US Food and Drug Administration. Guidance for Industry, Bioanalytical Method Validation. 2018.
• 21 International Conference on Harmonization (ICH), Q2 (R1): Text on Validation of Analytical Procedures. US FDA Federal Register; 2005
• 22 Yan F, Sun MM, Hang TJ, Sun J, Zhou X, Deng X, Ge L, Qian H, Ya D, Huang WL. A rapid and sensitive UPLC-MS/MS method for determination of HZ08 in rat plasma and tissues: application to a pharmacokinetic study of liposome injections. J Pharm Biomed Anal 2015; 102: 246-252